RNF213 governs divergent tumor-immune dynamics across human cancers: a prognostic biomarker for immunotherapy stratification.

Discov Oncol · 2025 · PMC12287489 · PMID 40699477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Moreover, in patients receiving a combination of anti-PD-1 and anti-CTLA-4 therapies, high RNF213 expression was correlated with a notably longer OS, yielding a highly significant P-value of 1.2e-5 (FDR = 1%) (Fig. 8 E).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.